EUDA Health Holdings (EUDA) Research & Development (2022 - 2023)
EUDA Health Holdings' (EUDA) quarterly Research & Development came in at -$27299.0 in Q2 2023, down 109.66% year-over-year from $282708.0 in Q2 2022, and down 106.74% quarter-over-quarter from $404771.0 in Q1 2023.
Powered by 
Analysis
EUDA Health Holdings (EUDA) Research & Development (2022 - 2023) Analysis & Trends
EUDA Health Holdings (EUDA) has reported Research & Development for 2 consecutive years, with -$27299.0 the latest figure, recorded in Q2 2023.
- On a quarterly basis, Research & Development fell 109.66% year-over-year to -$27299.0 in Q2 2023; TTM through Jun 2023 was $1.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.3 million, up 888.54% from the prior year.
- Research & Development was -$27299.0 for Q2 2023 at EUDA Health Holdings, down from $404771.0 in the prior quarter.
- Over five years, Research & Development peaked at $404771.0 in Q1 2023 and troughed at -$27299.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.74 Bn | 11.05 Bn | 1.16 Bn | - |
| 2 | RadNet | 5.78 Bn | 5.06 Bn | 88.08 Mn | - |
| 3 | Fresenius Medical Care AG | 4.79 Bn | 4.09 Bn | 1.52 Bn | 46.06 Mn |
| 4 | Concentra Group Holdings Parent | 4.28 Bn | 4.12 Bn | 192.10 Mn | - |
| 5 | Privia Health | 2.57 Bn | 2.16 Bn | - | 8.00 Mn |
| 6 | Progyny | 2.12 Bn | 1.88 Bn | 89.30 Mn | 18.07 Mn |
| 7 | Pediatrix Medical | 2.12 Bn | 1.71 Bn | - | - |
| 8 | Surgery Partners | 1.82 Bn | 1.60 Bn | 622.10 Mn | - |
| 9 | U S Physical Therapy | 1.17 Bn | 1.15 Bn | 41.94 Mn | - |
| 10 | EUDA Health Holdings | 23.79 Mn | 23.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -27,299.00 |
| Mar 31, 2023 | 404,771.00 |
| Jun 30, 2022 | 282,708.00 |
| Mar 31, 2022 | 368,092.00 |